Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of PEDMARK TM (a unique formulation of Sodium Thiosulfate) for the prevention of ototoxicity from cisplatin in pediatric patients.
PEDMARK is an investigational drug and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Publications & Presentations
Helping the Kids of Today Become the Adults of Tomorrow
Hearing loss is a devastating and life-long impact on quality of life for children that can cause grade setbacks and learning problems. Fennec advocates for a better quality of life.
Fennec News
- September 21st, 2020 FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR PEDMARK™
- August 12th, 2020 Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
- August 11th, 2020 Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors